The ECLA/PHRI Intervention in the Community Trial

Hypertension Clinical Trial

— EPIC  

Official title:

The ECLA/PHRI Intervention in the Community Trial - EPIC Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05638009
• Other study ID #: EPIC. Version 2.0
• Status: Recruiting
• Phase: N/A
• Start date: November 14, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: December 2022
• Source: Estudios Clínicos Latino América
• Contact: María Luz Diaz, MD
• Phone: +54 9 341605-3295
• Email: marialuzdiaz02[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

EPIC is a cluster-randomized, double-blind trial to evaluate the effect of two potassium-enriched salt substitute preparations (one available in the Argentine market and one derived from it), compared to regular salt on systolic blood pressure in subjects ≥ 18 and ≤ 90 years old from Rosario department households in Santa Fe Province, Argentina.

Description:

The effect of reduced sodium salt preparations has been evaluated in clinical studies (observational and randomized clinical trials) and in meta-analyses, and although a reduction in blood pressure was observed, they have particular characteristics that make them difficult to extrapolate their results to Western populations. In one of these trials, conducted in rural Indian hypertensive patients, the use of a salt substitute of 75% sodium chloride and 25% potassium chloride showed a significant reduction of systolic blood pressure with a mean difference of -4.58 mmHg in 3 months from baseline to the end of the trial. Recently, a large cluster-randomized trial conducted in 600 villages in rural areas of five provinces of China (SSaSS trial) among patients with a history of stroke or 60 years of age or elder with elevated blood pressure showed that stroke rates, major cardiovascular events and death from any cause were significantly lower with a salt substitute than with regular salt. The salt substitute used in this trial had 1/3 less sodium than regular salt and substantially more potassium. Therefore, the salt substitute led to an 8% less sodium intake but a 50% higher intake in potassium. This suggests that the greatest impact of salt substitution in this RCT may have been due to an increase in potassium intake rather than the modest decrease in sodium intake that was associated with an average reduction of 2.65 mmHg for SBP (-4.32 to -0.97) and +0.30 mmHg (-0.72 to +1.32) for DBP. In addition, the mean sodium intake in the studied population in this trial was approximately 4.2 gr/d, which is higher than the global average worldwide sodium consumption of 3.9 gr/d. In contrast, potassium intake was lower than the average global potassium intake. Therefore, several considerations that limit the applicability to other populations remain unresolved. The sodium intake of the Chinese rural population is higher than in many other countries, while the potassium intake is relatively low. In addition, in many countries commercially available foods may have added sodium chloride for preservation and thus increase the amount of sodium to the diet. Therefore, the use of salt substitutes would not fully account for salt intake in most cases. Finally, Chinese social and environmental features may be somewhat different to most western countries. EPIC's investigators stated the hypothesis that salt substitutes could lower systolic blood pressure in a dose-response mode. Therefore, they propose to conduct a randomized cluster trial to evaluate the effect of consuming two doses enriched potassium salt substitutes preparations compared to regular salt intake on systolic blood pressure in individuals from Rosario department.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2490
• Est. completion date: June 30, 2023
• Est. primary completion date: April 14, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Subjects = 18 and = 90 years old will be included, with no specific clinical conditions

from households that meets the following criteria:

• The household must be composed of at least 2 individuals
• At least 1 of the individuals included must be over 40 years of age
• The household must be located in Rosario department, Santa Fe province, Argentina Exclusion Criteria: Households will be excluded if a any household member has a at least one of the following

contraindication to the salt substitute used in the trial:

• use of a potassium-sparing diuretic
• use of a potassium supplement
• known history of hyperkalemia
• use of salt reduced in sodium and enriched in potassium by medical indication
• do not consume any type of salt for medical indication
• known primary or secondary hyperaldosteronism
• known severe kidney disease (routine biochemical measurement of kidney function will not be performed in household members not included in the study).
• Pregnancy or lactation
• Evidence of hyperkalemia and/or a creatinine clearance (calculated through the CKD-EPI formula <30 ml/min/1.73m2) in baseline blood laboratory. For those participants who consent to be tested, blood sample will be used. For those participant who has a laboratory test performed with those biomarkers in the past 6 months those results will be considered
• Households in which any of the study participants consume more than 50% of their meals prepared outside their home will also be excluded.

Related Conditions & MeSH terms

• Hypertension

Intervention

Dietary Supplement:
• Salt substitute 66%33%
Salt substitute composed of 66% potassium chloride and 33% sodium chloride
• Salt substitute 33%/66%
Salt substitute composed of 33% potassium chloride and 66% sodium chloride

Locations

Country	Name	City	State
Argentina	IIC-Instituto de Investigaciones Clínicas	Rosario	Santa Fe

Sponsors (2)

Lead Sponsor	Collaborator
Estudios Clínicos Latino América	Population Health Research Institute

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Systolic Blood Pressure at day 120	Systolic Blood Pressure will be measured by a standardized automated device	120 days
Secondary	Hyperkalemia	Evidence of Hyperkalemia is determined by clinical suspicion or biochemical value defined as a serum potassium value above 5.5 mmol/l (in case it is measured) during the follow up.	120 days
Secondary	Salt substitutes acceptance and incorporation into the diet	Salt substitutes acceptance and incorporation into the diet will be measured through a questionnaire administrated at 30 days and follow-up.; The questionnaire includes the following questions: How many days in the last week did you use study salt? If you were meant to use the study salt in the last week but did not use it every day, what is the reason? If you use the study salt in the last week: How did you use it? How many meals did you use the study salt during the day? Did you enjoy the taste? (1 = disliked a lot; 10 = liked a lot)	120 days
Secondary	Diastolic Blood Pressure at day 120	Diastolic Blood Pressure will be measured by a standardized automated device	120 days
Secondary	Mean arterial pressure (MAP) at day 120	Systolic and Diastolic Blood Pressure will be measured by a standardized automated device in order to compute MAP	120 days